The pattern of infection and in vivo response to Chloroquine by uncomplicated Plasmodium falciparum malaria in northwestern Nigeria

African Journal of Biotechnology

Volumn 4, Issue 1, 2005, Pages 79-82

  Bello, S O ^a,b   Muhammad, B Y ^a   Bello, A Y ^c   Ukatu, A I ^d   Ahmad, B M ^e   Adeneye, A A ^a,f   Cherima, J Y ^g  

^a USMANU DANFODIYO UNIVERSITY   (Nigeria)

^b Karaye Hospital   (Nigeria)

^c Sokoto Specialist Hospital   (Nigeria)

^d Mayo Clinic and Maternity   (Nigeria)

^e Women and Child Welfare Clinic   (Nigeria)

^f GENERAL HOSPITAL   (Nigeria)

^g General Hospital Wurno   (Nigeria)

Author keywords

Chloroquine; Plasmodium falciparum malaria; Resistance

Indexed keywords

CHLOROQUINE; FANSIDAR; HALOFANTRINE; QUININE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL TRIAL; EVALUATION; FEMALE; HUMAN; INFANT; MALARIA; MALE; NIGERIA; PLASMODIUM FALCIPARUM; RISK ASSESSMENT; TREATMENT FAILURE;

CINCHONA PUBESCENS; PLASMODIUM FALCIPARUM;

EID: 18244397444     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. National Institute of Health (2001). Policy and Guidelines on the inclusion of Children as participants in Research Involving Human Subjects. http://grants1.nih.gov/grants/guide/notice-files/NOT98-024.html.
2. Pratt BW (1990). Origin of Acquired Drug Resistance. In : Pratt BW , Taylor P (eds) Principles of drug Action-the basis of pharmacology. 3rd edn. Churchill Livingstone Inc, New York, pp 565-567.
3. Reither-Theil S (2001). The Freiburg approach to ethics consultation: process, outcome and competencies. J. Med. Ethics 27:i21-i23.
4. Shakoor O, Taylor RB, Behrens RH (1997) Assessment of the incidence of substandard drugs in developing countries. Trop. Med. Int. Health 2:839-845.
5. Taylor RB, Shakoor O, Behrens RH, Everard M, Low AS, Wangboonskul J et al (2001), Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 357:1933.
6. Toshihiro M, Akira K, Lum KJ, Bwijo B, Takechi M, Zungu I I et al (2003). Recovery of Chloroquine Sensitivity and low prevalence of the Plasmodium falciparum Chloroquine resistance transporter gene mutation K76T following the discontinuance of Chloroquine use in Malawi. Am. J. Trop. Med. Hyg. 68(4): 413-415.
7. World Health Organization (2003). Africa Malaria Report 2003. http://www.rbm.who.int/amd2003/amr2003/ch3.htm.
8. World Health Organization (2001). Monitoring Antimalarial Drug Resistance. http://www.who.int/emc.
9. World Health Organization (2000). Severe falciparum malaria. Trans. Roy. Soc. Trop. Med. Hyg. 94 (Suppl): S1/1-S1/90.
10. World Health Organization (1996). Management of uncomplicated malaria and the use of antimalarial drugs for the protection of travelers. WHO/MAL/96.1075.
11. World Health Organization (1995). Guidelines for good clinical practice for trials on pharmaceutical products. WHO Technical report Series, Number 850, WHO, Geneva.
12. Zucker JR, Ruebush II TK, Obonyo C, Otieno J, Campbell CC (2003). The mortality consequences of the continued use of Chloroquine in Africa; experience in Siaya, Western Kenya. Am. J. Trop. Med. Hyg. 68(4): 386-390.